Every credible alternative to SkinnyRx sits in one of three channels: compounded telehealth platforms, manufacturer self-pay pharmacies, and clinician-led weight programs that write for approved products. Total value is decided by which channel a buyer joins, not by which brand inside it advertises the lowest monthly figure. The channel sets the drug, the regulatory status, and the twelve-month cost.
The three channels, and what each one actually sells
Compounded telehealth platforms sell physician-supervised access to compounded semaglutide or tirzepatide at cash prices, shipped monthly. Names in this group include Henry Meds, Mochi Health, Eden, and a long tail of smaller operators. The medication is not FDA-approved, and the agency has said plainly that it has not reviewed these preparations for safety, effectiveness, or manufacturing quality.
Manufacturer self-pay pharmacies are the second channel. Eli Lilly sells Zepbound vials through LillyDirect and Novo Nordisk sells Wegovy through NovoCare Pharmacy, both at published self-pay rates well below list. These dispense approved products with approved labeling, which removes the entire regulatory question from the decision.
The third channel is clinician-led programs, including Found, Calibrate, Noom Med, WeightWatchers Clinic, Ro, and Hims and Hers. These charge for the clinical relationship and route the prescription wherever coverage or cash price lands, sometimes to a retail pharmacy, sometimes to a manufacturer channel. The membership buys management rather than molecules.
Comparing names within the compounded channel comes down to reading each order page directly. HealthRX, for example, presents its GLP-1 medications and the terms attached to them in one place, which makes it straightforward to set against Henry Meds, Mochi Health, or Eden on molecule, strength-based pricing, and refill cadence. A side-by-side of that kind stays honest only when each figure is taken from the provider’s current page rather than a secondhand summary.
Score the year, not the month
Monthly figures are close to useless for comparison because the channels bundle differently. A twelve-month total needs five lines: medication at the strength expected by month six, any recurring membership, consult and follow-up charges, laboratory testing, and shipping. Two programs advertising the same monthly number can land several hundred dollars apart once those lines are filled in.
Dose escalation is what breaks naive comparisons. The pivotal obesity trials for semaglutide and tirzepatide both used staged titration over months rather than a fixed strength, and prescribing in practice follows the same shape. Where a platform prices by strength, the month-twelve figure is the one that matters. Where it prices flat, the entry figure holds.
| Value dimension | Compounded telehealth | Manufacturer self-pay | Clinician-led program |
|---|---|---|---|
| Product status | Not FDA-approved | FDA-approved with approved labeling | Usually approved product |
| Typical price driver | Molecule and sometimes strength | Fixed per-vial self-pay rate | Membership plus whatever the drug costs |
| Clinical contact | Asynchronous messaging | Prescriber sourced separately | Scheduled visits and coaching |
| Insurance | Rarely billed | Not billed on the self-pay route | Often attempted first |
| Who to verify | Prescriber and compounding pharmacy | Prescriber only | Prescriber and clinical staffing |
| Main downside | Regulatory status of the preparation | Higher cash outlay | Membership continues if the drug does not |
Verifiability is a value dimension, not a formality
A cheap program that will not name its prescriber or its pharmacy has lower total value than a costlier one that names both, because the buyer is paying for something unverifiable. The two checks are quick. A named clinician can be looked up on the issuing state board register for license status and disciplinary history. A named pharmacy can be checked against its state board of pharmacy, or against the FDA register if it operates as an outsourcing facility.
LegitScript certification is a third signal worth understanding correctly. It is a paid, audited certification that payment processors and ad platforms require of healthcare merchants, and it can be checked on the certifying body’s own lookup. Holding it says a merchant passed that audit. Not holding it is common across the category and is not by itself evidence of anything, which is why it belongs in the scoring alongside licensure rather than in place of it.
Where the field genuinely differs
Comparisons written by competitors are a legitimate starting point provided the conflict is disclosed and every figure is confirmed at the source. One cash-pay compounded provider, formblends.com, maintains a side-by-side page setting SkinnyRx against other platforms on price and pathway, and it states on the page that it competes in the same market. Read that kind of document for the structure of the comparison, then rebuild the numbers from each provider’s current order page, because advertised rates in this sector change on a promotional cycle rather than an annual one.
The differences that survive that exercise are usually four. Whether the price is tiered by dose. Whether a membership continues billing during a pause. Whether laboratory work is included, requested, or ignored. And whether the program has a stated plan for continuity if its supply route changes, which matters more than it sounds given how much compounded supply has moved with FDA shortage determinations.
When the cheapest channel is the wrong answer
Compounded pricing sits below approved products because of the regulatory difference, not because of a manufacturing discount on an identical item. Published pharmacovigilance work on compounded GLP-1 products and a poison center case series on dosing errors both point at the same failure mode, which is patients handling concentrations and syringe markings that differ from approved presentations. Programs that ship without clear labeling and a titration plan carry that risk regardless of price.
For anyone with employer coverage worth testing, the arithmetic can invert entirely. Medicare has historically excluded drugs used only for weight loss, but commercial plans vary widely, and a covered approved product with a copay usually beats every cash channel on twelve-month cost. That check costs one phone call and should happen before any program is compared at all.
Frequently asked questions
Is a compounded platform always cheaper than the manufacturer route?
Usually on the monthly figure, not always across a year once membership, labs, and dose escalation are added. Manufacturer self-pay rates for Zepbound and Wegovy have moved downward and are published directly. Building both twelve-month totals takes a few minutes and often changes the answer.
What does LegitScript certification actually prove?
That a healthcare merchant passed a paid audit covering licensure, prescribing practices, and advertising claims, which payment processors and major ad platforms require. It is a meaningful positive signal and searchable on the certifier’s lookup. Its absence is common in this category and is not proof of wrongdoing.
Do clinician-led memberships include the medication?
Generally no. Programs such as Found, Calibrate, and WeightWatchers Clinic charge for clinical management and coaching, then the medication is billed separately through insurance or cash. The membership can keep charging during months when no prescription is filled, which is the line most often missed in comparisons.
How much weight difference is there between the molecules?
Semaglutide and tirzepatide were studied in separate trials with different populations, so cross-trial numbers should not be read as a head-to-head result. A later randomized comparison of the two in overweight and obese adults exists and is the better reference for anyone weighing molecule choice with a prescriber.
What is the fastest way to disqualify a provider?
Ask two questions in writing before paying: name the prescriber and their license state, and name the dispensing pharmacy. A provider that answers both has given a buyer two public records to check. A provider that declines has removed the only independent verification available.
Sources
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/medications-containing-semaglutide-marketed-type-2-diabetes-or-weight-loss
- FDA, Compounding Laws and Policies. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- FDA, Registered Outsourcing Facilities. https://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities
- Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. https://pubmed.ncbi.nlm.nih.gov/38976257/
- Tirzepatide Once Weekly for the Treatment of Obesity, SURMOUNT-1. https://pubmed.ncbi.nlm.nih.gov/35658024/
- Once-Weekly Semaglutide in Adults with Overweight or Obesity, STEP 1. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Safety analysis of compounded GLP-1 receptor agonists, pharmacovigilance study. https://pubmed.ncbi.nlm.nih.gov/40285721/
- Administration errors of compounded semaglutide reported to a poison control center. https://pubmed.ncbi.nlm.nih.gov/37392810/
- CMS, Prescription Drug Coverage General Information. https://www.cms.gov/medicare/coverage/prescription-drug-coverage
- DailyMed, Zepbound prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ZEPBOUND
- DailyMed, Mounjaro prescribing information. https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=MOUNJARO
- LegitScript, Healthcare Merchant Certification. https://www.legitscript.com/certification/healthcare-merchant-certification/
